2002/2171(COS)) The European Parliament , – having regard to the Commission communication ( COM(2001) 666 – C5‑0327/2002 OJ not yet published. ), – having regard to Article 152 of the Treaty, – having regard to Directive 93/42/EEC of the Council of 14 June 1993 concerning medical devices OJ L 169, 12.7.1993, p. 1 , – having regard to Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices OJ L 331, 7.12.1998, p. 1 , – having regard to Directive 2000/70/EC of the European Parliament and of the Council of 16 November 2000 amending Council Directive 93/42/EEC as regards medical devices incorporating stable derivates of human blood or human plasma OJ L 313, 13.12.2000, p. 22 , – having regard to its resolution of 13 June 2001 on the petitions declared admissible, concerning silicone implants (Petitions 0470/1998 and 0771/1998) OJ C 53, 28.2.2002, p. 21. , – having regard to Rule 47(1) of its Rules of Procedure, – having regard to the report of the Committee on the Environment, Public Health and Consumer Policy and the opinions of the Committee on Women's Rights and Equal Opportunities and the Committee on Petitions ( A5‑0008/2003 ), A. whereas there is a lack of information on the potential risks with breast implants, B. whereas thousands of women have petitioned the European Parliament to take a stand on the dangers inherent in the use of silicone breast implants, C. whereas, in its resolution of 13 June 2001, the European Parliament focused in particular on the safety and quality of products and pre- and post-operative support, recommending a number of specific measures at Community and national level, D. whereas patients need to know that, for some patients, implants are not for life and may need to be replaced or removed; whereas patients also need to be informed about implant quality and the suitability of implants for the patient concerned, E. whereas rupture occurs significantly, from 5-51% according to studies. Some studies point to a rupture rate of 50% after 7-10 years and up to 95% after 20 years, F. whereas many women have implants for cosmetic purposes and self-help groups argue that if fuller information on risks and implications was given before surgery fewer women would opt for implants, G. whereas lack of registration of implants in Europe means that the overall numbers of women with implants are unknown, H. whereas there are shortcomings of the existing research, e.g., lack of long-term data, no figures for numbers of implants, mixing of different implant types in studies, and insufficient information about the durability of implants, 1. Calls for no complete ban, but the adoption and implementation of critical specific measures to improve information for patients, tracking and surveillance, quality control and assurance and key research on silicone breast implants and their components, and on their clinical evaluation after they are placed on the market, in particular into: - the life span of implants; - better protection of the health of implant recipients; and - full assessment of the